Brief: Zealand Pharma, Roche To Advance petrelintide To Phase 3 Trials For Chronic Weight Management
29/04/2026 18:35
April 29 (Reuters) - Zealand Pharma A/S ZELA.CO: ZEALAND PHARMA AND ROCHE TO ADVANCE PETRELINTIDE, AN AMYLIN ANALOG, TO PHASE 3 TRIALS FOR CHRONIC WEIGHT MANAGEMENT ZEALAND PHARMA AND ROCHE TO ADVANCE PETRELINTIDE, AN AMYLIN ANALOG, TO PHASE 3 TRIALS FOR CHRONIC WEIGHT MANAGEMENT ZEALAND PHARMA - PHASE 2 TRIAL OF PETRELINTIDE AND ENICEPATIDE COMBINATION PLANNED FOR INITIATION IN Q2 2026 ZEALAND PHARMA - PETRELINTIDE DEMONSTRATED DOUBLE-DIGIT WEIGHT LOSS WITH PLACEBO-LIKE TOLERABILITY IN ZUPREME-1 PHASE 2 TRIAL Source text: ID:nGNX7tyWtW Further company coverage: ZELA.CO ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza